Search

Search Constraints

You searched for: Author/Creator Paré, Laia

Search Results

1. 806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. (9th November 2020)

2. 806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. (9th November 2020)

3. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Issue 11 (November 2020)

4. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. Issue 13 (1st May 2021)

5. Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial. Issue 1 (19th June 2019)

6. Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2. (24th January 2019)

7. Gene expression profiles of breast cancer metastasis according to organ site. Issue 1 (23rd June 2021)

8. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. (30th April 2019)

9. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Issue 4 (April 2017)

10. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. (28th December 2022)